BOOKS BY CATEGORY
Your Account
Advances in Cancer Research: Volume 142
Price
Quantity
£119.00
(To see other currencies, click on price)
Hardback
Add to basket  

£119.00
(To see other currencies, click on price)
PDF
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Advances in Cancer Research, Volume 142, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research. Provides information on cancer research, offers outstanding and original reviews on a range of cancer research topics. Serves as an indispensable reference for researchers and students alike with key topics covered such as basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.


Contents:

1. Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patients
Jayashri Ghosh, Bryant Schultz, Christos Coutifaris and Carmen Sapienza

2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations Ryan M. Phillips, Christine Lam, Hailun Wang and Phuoc T. Tran

3. The second genome: Effects of the mitochondrial genome on cancer progression Adam D. Scheid, Thomas C. Beadnell and Danny R. Welch

4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors
Manny D. Bacolod, Francis Barany, Karsten Pilones, Paul B. Fisher and Romulo J. de Castro

5. HVEM network signaling in cancer
John R. Sedy and Parham Ramezani-Rad

6. Pharmacology of ME-344, a novel cytotoxic isoflavone
Leilei Zhang, Jie Zhang, Zhiwei Ye, Danyelle M. Townsend and Kenneth D. Tew


PRODUCT DETAILS

ISBN-13: 9780128171530
Publisher: Elsevier (Elsevier Science Publishing Co Inc)
Publication date: March, 2019
Pages: 217
Weight: 480g
Availability: Available
Subcategories: Genetics, Immunology

MEET THE AUTHOR

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 600 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy ("theranostics") of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018). Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USAThe Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

CUSTOMER REVIEWS

Average Rating